Interesting that they list the US for other indications, but not respiratory:
Respiratory Disease
Paradigm Biopharmaceuticals Ltd has acquired patents over the use of PPS as a new treatment for respiratory diseases including Allergic Rhinitis (AR), Allergic Asthma (AA) and Chronic Obstructive Pulmonary Disease (COPS). Paradigm has registered patents in major markets including Australia, Canada, Europe, New Zealand, and The People’s Republic of China.
W
Interesting that they list the US for other indications, but not...
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
-0.015(5.26%) |
Mkt cap ! $94.58M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.5¢ | 27.0¢ | $127.6K | 455.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 66463 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 6800 | 1 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
27.5¢ |
Change
-0.015 ( 3.51 %) |
||||
| Open | High | Low | Volume | ||
| 28.5¢ | 29.0¢ | 27.5¢ | 116032 | ||
| Last updated 15.55pm 26/04/2024 ? | |||||
| PAR (ASX) Chart |